These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
217 related items for PubMed ID: 1720809
1. Role of human decay-accelerating factor in the evasion of Schistosoma mansoni from the complement-mediated killing in vitro. Horta MF, Ramalho-Pinto FJ. J Exp Med; 1991 Dec 01; 174(6):1399-406. PubMed ID: 1720809 [Abstract] [Full Text] [Related]
2. Mechanisms of evasion of Schistosoma mansoni schistosomula to the lethal activity of complement. Ramalho-Pinto FJ, Carvalho EM, Horta MF. Mem Inst Oswaldo Cruz; 1992 Dec 01; 87 Suppl 4():111-6. PubMed ID: 1285336 [Abstract] [Full Text] [Related]
3. Decay accelerating factor (DAF) as the host antigen with protective activity to complement killing of schistosomula. Ramalho-Pinto FJ. Mem Inst Oswaldo Cruz; 1987 Dec 01; 82 Suppl 4():213-6. PubMed ID: 2474124 [Abstract] [Full Text] [Related]
4. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum. Wilcox LA, Ezzell JL, Bernshaw NJ, Parker CJ. Blood; 1991 Aug 01; 78(3):820-9. PubMed ID: 1713516 [Abstract] [Full Text] [Related]
5. Host-specific evasion of the alternative complement pathway by schistosomes correlates with the presence of a phospholipase C-sensitive surface molecule resembling human decay accelerating factor. Pearce EJ, Hall BF, Sher A. J Immunol; 1990 Apr 01; 144(7):2751-6. PubMed ID: 1690776 [Abstract] [Full Text] [Related]
6. Binding of GPI-PLD-treated DAF to the surface of Schistosoma mansoni schistosomula. Carvalho EM, Metz CN, Davitz MA, Ramalho-Pinto FJ. Braz J Med Biol Res; 1994 Feb 01; 27(2):457-62. PubMed ID: 7521707 [Abstract] [Full Text] [Related]
7. Studies on the sensitivity to complement-mediated lysis of erythrocytes (Inab phenotype) with a deficiency of DAF (decay accelerating factor). Merry AH, Rawlinson VI, Uchikawa M, Daha MR, Sim RB. Br J Haematol; 1989 Oct 01; 73(2):248-53. PubMed ID: 2479410 [Abstract] [Full Text] [Related]
8. Phospholipid-anchored and transmembrane versions of either decay-accelerating factor or membrane cofactor protein show equal efficiency in protection from complement-mediated cell damage. Lublin DM, Coyne KE. J Exp Med; 1991 Jul 01; 174(1):35-44. PubMed ID: 1711565 [Abstract] [Full Text] [Related]
9. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. Davitz MA, Low MG, Nussenzweig V. J Exp Med; 1986 May 01; 163(5):1150-61. PubMed ID: 2422313 [Abstract] [Full Text] [Related]
10. Complement regulation on the surface of cultured schistosomula and adult worms of Schistosoma mansoni. Marikovsky M, Parizade M, Arnon R, Fishelson Z. Eur J Immunol; 1990 Jan 01; 20(1):221-7. PubMed ID: 2307175 [Abstract] [Full Text] [Related]
11. Induction of the paroxysmal nocturnal hemoglobinuria phenotype in normal human erythrocytes: effects of 2-aminoethylisothiouronium bromide on membrane proteins that regulate complement. Ezzell JL, Wilcox LA, Bernshaw NJ, Parker CJ. Blood; 1991 Jun 15; 77(12):2764-73. PubMed ID: 1710519 [Abstract] [Full Text] [Related]
12. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9. Shin ML, Hänsch G, Hu VW, Nicholson-Weller A. J Immunol; 1986 Mar 01; 136(5):1777-82. PubMed ID: 2419414 [Abstract] [Full Text] [Related]
13. Heightened complement sensitivity of acquired immunodeficiency syndrome lymphocytes related to diminished expression of decay-accelerating factor. Lederman MM, Purvis SF, Walter EI, Carey JT, Medof ME. Proc Natl Acad Sci U S A; 1989 Jun 01; 86(11):4205-9. PubMed ID: 2471198 [Abstract] [Full Text] [Related]
14. Protection of human nasal respiratory epithelium from complement-mediated lysis by cell-membrane regulators of complement activation. Varsano S, Frolkis I, Rashkovsky L, Ophir D, Fishelson Z. Am J Respir Cell Mol Biol; 1996 Dec 01; 15(6):731-7. PubMed ID: 8969267 [Abstract] [Full Text] [Related]
15. Presence of human chromosome 1 with expression of human decay-accelerating factor (DAF) prevents lysis of mouse/human hybrid cells by human complement. Wang MW, Wright LJ, Sims MJ, White DJ. Scand J Immunol; 1991 Dec 01; 34(6):771-8. PubMed ID: 1721235 [Abstract] [Full Text] [Related]
16. Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. Medof ME, Kinoshita T, Nussenzweig V. J Exp Med; 1984 Nov 01; 160(5):1558-78. PubMed ID: 6238120 [Abstract] [Full Text] [Related]
18. Structural and functional differences between decay-accelerating factor and red cell acetylcholinesterase. Sugarman J, Devine DV, Rosse WF. Blood; 1986 Sep 01; 68(3):680-4. PubMed ID: 2427138 [Abstract] [Full Text] [Related]
19. Reduced activity of DAF on complement enzymes bound to alternative pathway activators. Similarity with Factor H. Pangburn MK. Immunology; 1990 Dec 01; 71(4):598-600. PubMed ID: 1703989 [Abstract] [Full Text] [Related]
20. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor. Holguin MH, Martin CB, Bernshaw NJ, Parker CJ. J Immunol; 1992 Jan 15; 148(2):498-502. PubMed ID: 1370313 [Abstract] [Full Text] [Related] Page: [Next] [New Search]